myelofibrosis

GERN Earnings – Q2 2026

ArctosFXAdmin / August 6, 2026

Geron Corporation (Nasdaq: GERN) reported second-quarter results on August 5, 2026, showing continued commercial progress for its telomerase inhibitor RYTELO

Analysis, Stocks

Geron Corp. (GERN)

ArctosFXAdmin / March 27, 2026

Geron Corp. (NASDAQ: GERN) is a commercial-stage biopharmaceutical company dedicated to changing the lives of patients by changing the course of

ARCTOS FX LLC is registered as a Commodity Trading Advisor (CTA) with the National Futures Association. Trading foreign exchange on margin carries a high level of risk and may not be suitable for all investors. Past performance is not indicative of future results.

myelofibrosis

GERN Earnings – Q2 2026

Geron Corp. (GERN)

© 2026 Arctos FX